Wählen Sie Ihren Standort:

Zanubrutinib + Venetoclax for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Patients With del(17p) and/or TP53 Mutation and Unmutated Immunoglobulin Heavy-Chain Variable Status: 3-Year Results From SEQUOIA Arm D